Arax Advisory Partners’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $56.2M | Buy |
46,821
+39,823
| +569% | +$40.7M | 0.37% | 47 |
|
|
2026
Q1 | $6.44M | Sell |
6,998
-1,690
| -19% | -$1.71M | 0.18% | 114 |
|
|
2025
Q4 | $9.34M | Sell |
8,688
-13,875
| -61% | -$13.3M | 0.27% | 78 |
|
|
2025
Q3 | $17.2M | Buy |
22,563
+19,528
| +643% | +$14.5M | 0.25% | 55 |
|
|
2025
Q2 | $2.94M | Buy |
3,035
+568
| +23% | +$441K | 0.13% | 121 |
|
|
2025
Q1 | $2.04M | Sell |
2,467
-206
| -8% | -$171K | 0.13% | 112 |
|
|
2024
Q4 | $2.06M | Buy |
2,673
+208
| +8% | +$172K | 0.13% | 105 |
|
|
2024
Q3 | $2.18M | Buy |
2,465
+18
| +0.7% | +$16.2K | 0.2% | 67 |
|
|
2024
Q2 | $2.22M | Buy |
2,447
+495
| +25% | +$396K | 0.22% | 65 |
|
|
2024
Q1 | $1.52M | Sell |
1,952
-45
| -2% | -$32K | 0.16% | 74 |
|
|
2023
Q4 | $1.16M | Sell |
1,997
-153
| -7% | -$89.3K | 0.13% | 92 |
|
|
2023
Q3 | $1.15M | Sell |
2,150
-34
| -2% | -$17.5K | 0.14% | 78 |
|
|
2023
Q2 | $1.02M | Buy |
2,184
+8
| +0.4% | +$3.35K | 0.13% | 79 |
|
|
2023
Q1 | $747K | Buy |
2,176
+97
| +5% | +$32.7K | 0.1% | 92 |
|
|
2022
Q4 | $761K | Buy |
2,079
+119
| +6% | +$42.2K | 0.11% | 87 |
|
|
2022
Q3 | $634K | Sell |
1,960
-545
| -22% | -$173K | 0.1% | 87 |
|
|
2022
Q2 | $812K | Buy |
2,505
+890
| +55% | +$267K | 0.12% | 80 |
|
|
2022
Q1 | $462K | Buy |
1,615
+18
| +1% | +$4.63K | 0.06% | 107 |
|
|
2021
Q4 | $441K | Buy |
1,597
+3
| +0.2% | +$761 | 0.06% | 122 |
|
|
2021
Q3 | $368K | Buy |
1,594
+47
| +3% | +$11.6K | 0.05% | 136 |
|
|
2021
Q2 | $355K | Buy |
+1,547
| New | +$311K | 0.05% | 144 |
|
|
2020
Q4 | $259K | Buy |
1,532
+4
| +0.3% | +$597 | 0.04% | 171 |
|
|
2020
Q3 | $226K | Buy |
1,528
+99
| +7% | +$15.3K | 0.04% | 165 |
|
|
2020
Q2 | $235K | Buy |
1,429
+4
| +0.3% | +$614 | 0.04% | 155 |
|
|
2020
Q1 | $198K | Buy |
1,425
+826
| +138% | +$113K | 0.05% | 153 |
|
|
2019
Q4 | $79K | Hold |
599
| – | – | 0.02% | 275 |
|
|
2019
Q3 | $67K | Hold |
599
| – | – | 0.02% | 287 |
|
|
2019
Q2 | $66K | Buy |
+599
| New | +$70.5K | 0.02% | 286 |
|
|
2018
Q4 | $3K | Hold |
26
| – | – | ﹤0.01% | 514 |
|
|
2018
Q3 | $3K | Sell |
26
-623
| -96% | -$62.3K | ﹤0.01% | 550 |
|
|
2018
Q2 | $55K | Buy |
649
+214
| +49% | +$17.6K | 0.02% | 207 |
|
|
2018
Q1 | $33K | Buy |
435
+93
| +27% | +$7.49K | 0.02% | 243 |
|
|
2017
Q4 | $28K | Buy |
342
+73
| +27% | +$6.21K | 0.01% | 254 |
|
|
2017
Q3 | $23K | Sell |
269
-524
| -66% | -$43K | 0.01% | 266 |
|
|
2017
Q2 | $65K | Buy |
793
+227
| +40% | +$18.5K | 0.03% | 203 |
|
|
2017
Q1 | $47K | Buy |
566
+351
| +163% | +$28.1K | 0.02% | 212 |
|
|
2016
Q4 | $16K | Buy |
+215
| New | +$16K | 0.01% | 283 |
|
Other funds holding LLY
Arax Advisory Partners's LLY Position: Q2 2026 in Review
Arax Advisory Partners increased its Eli Lilly (LLY) stake by 569% in Q2 2026, buying an estimated $40.7M and bringing the position to 46,821 shares worth $56.2M. The position accounts for 0.37% of the portfolio, ranked #47.
Arax Advisory Partners first reported a position in LLY in Q4 2016 and has held it in 37 quarters since. 4,634 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Arax Advisory Partners held 46,821 shares of Eli Lilly worth $56.2M as of Q2 2026.
- Arax Advisory Partners bought 39,823 Eli Lilly shares in Q2 2026, an estimated $40.7M.
- Eli Lilly made up 0.37% of Arax Advisory Partners's portfolio in Q2 2026, its #47 holding.
- Arax Advisory Partners first reported a position in Eli Lilly in Q4 2016 and has held it in 37 quarters since.
- 4,634 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.